Result 1 - 10 of total 269
Clinical Therapeutics
| Keywords | covid19 |
|---|---|
| Publisher | WHO |
| Document type | Article |
| Note | WHO #Covidence: #832117 |
| Database | COVID19 |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of biological regulators and homeostatic agents
2021 Volume 35, Issue 3, Page(s) 833–838
Abstract: The COVID-19 pandemic necessitated the rapid production of vaccines aimed at the production of neutralizing antibodies against the COVID-19 spike protein required for the corona virus binding to target cells. The best well-known vaccines have utilized ... ...
| Abstract | The COVID-19 pandemic necessitated the rapid production of vaccines aimed at the production of neutralizing antibodies against the COVID-19 spike protein required for the corona virus binding to target cells. The best well-known vaccines have utilized either mRNA or an adenovirus vector to direct human cells to produce the spike protein against which the body produces mostly neutralizing antibodies. However, recent reports have raised some skepticism as to the biologic actions of the spike protein and the types of antibodies produced. One paper reported that certain antibodies in the blood of infected patients appear to change the shape of the spike protein so as to make it more likely to bind to cells, while other papers showed that the spike protein by itself (without being part of the corona virus) can damage endothelial cells and disrupt the blood-brain barrier. These findings may be even more relevant to the pathogenesis of long-COVID syndrome that may affect as many as 50% of those infected with SARS-CoV-2. In COVID-19, a response to oxidative stress is required by increasing anti-oxidant enzymes. In this regard, it is known that polyphenols are natural anti-oxidants with multiple health effects. Hence, there are even more reasons to intervene with the use of anti-oxidant compounds, such as luteolin, in addition to available vaccines and anti-inflammatory drugs to prevent the harmful actions of the spike protein. |
|---|---|
| Language | English |
| Publishing date | 2021-06-08 |
| Publishing country | Italy |
| Document type | Editorial |
| ZDB-ID | 639196-5 |
| ISSN | 1724-6083 ; 0393-974X |
| ISSN (online) | 1724-6083 |
| ISSN | 0393-974X |
| DOI | 10.23812/THEO_EDIT_3_21 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Journal of biological regulators and homeostatic agents
2020 Volume 34, Issue 3, Page(s) 1241–1243
Abstract: ... Defense against this Corona virus requires activated T cells and specific antibodies. Instead, cytokines ... the production of and damaging effect of the cytokines, but will also inhibit the protective function of T ...
| Abstract | Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only. The recent Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2]-associated multiorgan disease, called COVID-19, has high morbidity and mortality due to autoimmune destruction of the lungs stemming from the release of a storm of pro-inflammatory cytokines. Defense against this Corona virus requires activated T cells and specific antibodies. Instead, cytokines are responsible for the serious sequelae of COVID-19 that damage the lungs. Dexamethasone is a synthetic corticosteroid approved by the FDA 1958 as a broad-spectrum immunosuppressor and it is about 30 times as active and with longer duration of action (2-3 days) than cortisone. Dexamethasone would limit the production of and damaging effect of the cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS. Moreover, dexamethasone would block macrophages from clearing secondary, nosocomial, infections. Hence, dexamethasone may be useful for the short-term in severe, intubated, COVID-19 patients, but could be outright dangerous during recovery since the virus will not only persist, but the body will be prevented from generating protective antibodies. Instead, a pulse of intravenous dexamethasone may be followed by administration of nebulized triamcinolone (6 times as active as cortisone) to concentrate in the lungs only. These corticosteroids could be given together with the natural flavonoid luteolin because of its antiviral and anti-inflammatory properties, especially its ability to inhibit mast cells, which are the main source of cytokines in the lungs. At the end, we should remember that "The good physician treats the disease; the great physician treats the patient who has the disease" [Sir William Osler's (1849-1919)]. |
|---|---|
| MeSH term(s) | Betacoronavirus ; Coronavirus Infections/drug therapy ; Dexamethasone/therapeutic use ; Humans ; Pandemics ; Pneumonia, Viral/drug therapy |
| Chemical Substances | Dexamethasone (7S5I7G3JQL) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-06-18 |
| Publishing country | Italy |
| Document type | Editorial |
| ZDB-ID | 639196-5 |
| ISSN | 1724-6083 ; 0393-974X |
| ISSN (online) | 1724-6083 |
| ISSN | 0393-974X |
| DOI | 10.23812/20-EDITORIAL_1-5 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Journal of biological regulators and homeostatic agents
2020 Volume 34, Issue 5, Page(s) 1633–1636
Abstract: ... reported in children and named Multisystem Inflammatory Syndrome (MIS-C). Now the US Center ...
| Abstract | COVID-19 derives from infection with Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2] and is associated with high morbidity and mortality due to release of a storm of pro-inflammatory cytokines and thrombogenic agents resulting in destruction of the lungs. Many reports indicate that a considerable number of patients who are positive for SARS-CoV-2 are asymptomatic or have mild symptoms. However, increasing evidence suggests that many such patients who either recovered from or had mild symptoms after COVID-19 exhibit diffuse, multiorgan, symptoms months after the infection. These symptoms include malaise, myalgias, chest tightness, brain fog and other neuropsychiatric symptoms that were originally reported in children and named Multisystem Inflammatory Syndrome (MIS-C). Now the US Center for Disease Control (CDC) announced the recognition of a similar condition in adults, named Multisystem Inflammatory Syndrome (MIS-A). The symptoms characterizing these conditions are very similar to those associated with Mast Cell Activation Syndrome (MCAS, US ICD-110 code D89.42-idiopathic mast cell activation syndrome). Hence, the possibility of MCAS should be evaluated in any patient with MIS and/or multisystem inflammatory symptoms. In either case, these syndromes should be addressed with liposomal formulation (in olive pomace oil) of the flavone luteolin (e.g. PureLut® or FibroProtek®) together with the antihistamine rupatadine, which also has anti-platelet activating factor (PAF) activity and inhibits mast cells that have been implicated in the pathogenesis of cytokine storms in COVID-19. |
|---|---|
| MeSH term(s) | Adult ; Betacoronavirus ; Child ; Coronavirus Infections/pathology ; Cyproheptadine/administration & dosage ; Cyproheptadine/analogs & derivatives ; Humans ; Luteolin/administration & dosage ; Mastocytosis/drug therapy ; Mastocytosis/virology ; Pandemics ; Pneumonia, Viral/pathology ; Systemic Inflammatory Response Syndrome/drug therapy |
| Chemical Substances | rupatadine (2AE8M83G3E) ; Cyproheptadine (2YHB6175DO) ; Luteolin (KUX1ZNC9J2) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-10-06 |
| Publishing country | Italy |
| Document type | Editorial |
| ZDB-ID | 639196-5 |
| ISSN | 1724-6083 ; 0393-974X |
| ISSN (online) | 1724-6083 |
| ISSN | 0393-974X |
| DOI | 10.23812/20-EDIT3 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Journal of biological regulators and homeostatic agents
2018 Volume 32, Issue 6, Page(s) 1345–1347
Abstract: Stress and inflammation have become the curses of our times and are the main pathogenetic factors in multiple diseases that are often comorbid and include allergies and asthma, eczema and psoriasis, fibromyalgia syndrome, mast cell activation syndrome, ... ...
| Abstract | Stress and inflammation have become the curses of our times and are the main pathogenetic factors in multiple diseases that are often comorbid and include allergies and asthma, eczema and psoriasis, fibromyalgia syndrome, mast cell activation syndrome, irritable bowel syndrome, myalgic encephalomyelitis/chronic fatigue syndrome and autism spectrum disorder (ASD). Unfortunately, there are no effective drugs. Cross-talk between mast cells and microglia in the hypothalamus and amygdala could explain stress-induced inflammation. We recently showed that the "alarmin" IL-33 could play a major role through its synergistic action with the neuropeptide substance P to stimulate human mast cell secretion of the pro-inflammatory molecules IL-1β, TNF and VEGF. A new formulation using pure luteolin with Ashwagandha has now been developed and could be of significant benefit to patients suffering from these diseases. |
|---|---|
| MeSH term(s) | Amygdala ; Humans ; Hypothalamus ; Inflammation/physiopathology ; Inflammation/therapy ; Interleukin-1beta ; Interleukin-33 ; Luteolin/therapeutic use ; Mast Cells ; Microglia ; Plant Extracts ; Stress, Psychological/physiopathology ; Stress, Psychological/therapy ; Tumor Necrosis Factor-alpha ; Vascular Endothelial Growth Factor A |
| Chemical Substances | IL1B protein, human ; IL33 protein, human ; Interleukin-1beta ; Interleukin-33 ; Plant Extracts ; Tumor Necrosis Factor-alpha ; VEGFA protein, human ; Vascular Endothelial Growth Factor A ; Luteolin (KUX1ZNC9J2) ; Ashwagandha (V038D626IF) |
| Language | English |
| Publishing date | 2018-12-20 |
| Publishing country | Italy |
| Document type | Journal Article |
| ZDB-ID | 639196-5 |
| ISSN | 1724-6083 ; 0393-974X |
| ISSN (online) | 1724-6083 |
| ISSN | 0393-974X |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Journal of biological regulators and homeostatic agents
2020 Volume 33, Issue 6, Page(s) 1663–1667
| MeSH term(s) | Central Nervous System/drug effects ; Central Nervous System/physiopathology ; Child ; Child Development ; Flavonoids/therapeutic use ; Herbicides/adverse effects ; Humans ; Inflammation/complications ; Learning ; Lyme Disease/complications ; Mastocytosis/complications ; Metals, Heavy/adverse effects ; Mycotoxins/adverse effects ; Polyvinyl Chloride/adverse effects ; Virus Diseases/complications |
|---|---|
| Chemical Substances | Flavonoids ; Herbicides ; Metals, Heavy ; Mycotoxins ; Polyvinyl Chloride (9002-86-2) |
| Language | English |
| Publishing date | 2020-01-13 |
| Publishing country | Italy |
| Document type | Editorial |
| ZDB-ID | 639196-5 |
| ISSN | 1724-6083 ; 0393-974X |
| ISSN (online) | 1724-6083 |
| ISSN | 0393-974X |
| DOI | 10.23812/19-33n6Edit_Theoharides |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 2270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
J. biol. regul. homeost. agents
Abstract: ... Defense against this Corona virus requires activated T cells and specific antibodies. Instead, cytokines ... the production of and damaging effect of the cytokines, but will also inhibit the protective function of T ...
| Abstract | Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only. The recent Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2]-associated multiorgan disease, called COVID-19, has high morbidity and mortality due to autoimmune destruction of the lungs stemming from the release of a storm of pro-inflammatory cytokines. Defense against this Corona virus requires activated T cells and specific antibodies. Instead, cytokines are responsible for the serious sequelae of COVID-19 that damage the lungs. Dexamethasone is a synthetic corticosteroid approved by the FDA 1958 as a broad-spectrum immunosuppressor and it is about 30 times as active and with longer duration of action (2-3 days) than cortisone. Dexamethasone would limit the production of and damaging effect of the cytokines, but will also inhibit the protective function of T cells and block B cells from making antibodies, potentially leading to increased plasma viral load that will persist after a patient survives SARS. Moreover, dexamethasone would block macrophages from clearing secondary, nosocomial, infections. Hence, dexamethasone may be useful for the short-term in severe, intubated, COVID-19 patients, but could be outright dangerous during recovery since the virus will not only persist, but the body will be prevented from generating protective antibodies. Instead, a pulse of intravenous dexamethasone may be followed by administration of nebulized triamcinolone (6 times as active as cortisone) to concentrate in the lungs only. These corticosteroids could be given together with the natural flavonoid luteolin because of its antiviral and anti-inflammatory properties, especially its ability to inhibit mast cells, which are the main source of cytokines in the lungs. At the end, we should remember that "The good physician treats the disease; the great physician treats the patient who has the disease" [Sir William Osler's (1849-1919)]. |
|---|---|
| Keywords | covid19 |
| Publisher | WHO |
| Document type | Article |
| Note | WHO #Covidence: #32551464 |
| Database | COVID19 |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
J Biol Regul Homeost Agents
Abstract: ... in children and named Multisystem Inflammatory Syndrome (MIS-C) Now the US Center for Disease Control (CDC ...
| Abstract | COVID-19 derives from infection with Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2] and is associated with high morbidity and mortality due to release of a storm of pro-inflammatory cytokines and thrombogenic agents resulting in destruction of the lungs Many reports indicate that a considerable number of patients who are positive for SARS-CoV-2 are asymptomatic or have mild symptoms However, increasing evidence suggests that many such patients who either recovered from or had mild symptoms after COVID-19 exhibit diffuse, multiorgan, symptoms months after the infection These symptoms include malaise, myalgias, chest tightness, brain fog and other neuropsychiatric symptoms that were originally reported in children and named Multisystem Inflammatory Syndrome (MIS-C) Now the US Center for Disease Control (CDC) announced the recognition of a similar condition in adults, named Multisystem Inflammatory Syndrome (MIS-A) The symptoms characterizing these conditions are very similar to those associated with Mast Cell Activation Syndrome (MCAS, US ICD-110 code D89 42-idiopathic mast cell activation syndrome) Hence, the possibility of MCAS should be evaluated in any patient with MIS and/or multisystem inflammatory symptoms In either case, these syndromes should be addressed with liposomal formulation (in olive pomace oil) of the flavone luteolin (e g PureLut® or FibroProtek®) together with the antihistamine rupatadine, which also has anti-platelet activating factor (PAF) activity and inhibits mast cells that have been implicated in the pathogenesis of cytokine storms in COVID-19 |
|---|---|
| Keywords | covid19 |
| Publisher | WHO |
| Document type | Article |
| Note | WHO #Covidence: #836480 |
| Database | COVID19 |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Annals of clinical and translational neurology
2022 Volume 9, Issue 11, Page(s) 1838–1857
Abstract: ... HLA-A, HLA-C, HLA-DQA1, HLA-DRB1, and TYK2 are the common genes that gave significant results ... cytokine signaling pathways, and the T cell activation and Toll receptor signaling pathways. Protein class ...
| Abstract | COVID-19 and ME/CFS present with some similar symptoms, especially physical and mental fatigue. In order to understand the basis of these similarities and the possibility of underlying common genetic components, we performed a systematic review of all published genetic association and cohort studies regarding COVID-19 and ME/CFS and extracted the genes along with the genetic variants investigated. We then performed gene ontology and pathway analysis of those genes that gave significant results in the individual studies to yield functional annotations of the studied genes using protein analysis through evolutionary relationships (PANTHER) VERSION 17.0 software. Finally, we identified the common genetic components of these two conditions. Seventy-one studies for COVID-19 and 26 studies for ME/CFS were included in the systematic review in which the expression of 97 genes for COVID-19 and 429 genes for ME/CFS were significantly affected. We found that ACE, HLA-A, HLA-C, HLA-DQA1, HLA-DRB1, and TYK2 are the common genes that gave significant results. The findings of the pathway analysis highlight the contribution of inflammation mediated by chemokine and cytokine signaling pathways, and the T cell activation and Toll receptor signaling pathways. Protein class analysis revealed the contribution of defense/immunity proteins, as well as protein-modifying enzymes. Our results suggest that the pathogenesis of both syndromes could involve some immune dysfunction. |
|---|---|
| MeSH term(s) | Humans ; Fatigue Syndrome, Chronic/genetics ; Fatigue Syndrome, Chronic/metabolism ; COVID-19/genetics ; Cohort Studies ; Inflammation |
| Language | English |
| Publishing date | 2022-10-06 |
| Publishing country | United States |
| Document type | Systematic Review ; Journal Article ; Review |
| ZDB-ID | 2740696-9 |
| ISSN | 2328-9503 ; 2328-9503 |
| ISSN (online) | 2328-9503 |
| ISSN | 2328-9503 |
| DOI | 10.1002/acn3.51631 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2015 Volume 37, Issue 6, Page(s) 1374–1377
Abstract: ... BDCA3(+) dendritic cells. These human equivalents of the rodent CD8(+) T cells migrate to tissues ... with the subsequent activation of pathogenic CD8(+) T cells. However, MCs may have additional regulatory functions ...
| Abstract | Purpose: Malaria remains the most deadly human parasitic disease, mostly because of the mosquito-born protozoan parasite Plasmodium falciparum with ~627,000 deaths reported in 2012. Unfortunately, there is resistance to most drugs, and successful vaccines are still not developed. The role of the immune system is critical but poorly understood. Methods: One specific publication that reported a new way through which the immune system may promote malaria pathogenesis is discussed. Findings: Kenyan children with mild and severe malaria had increased plasma levels of the Flt3 ligand, a soluble cytokine released from the surface of mast cells (MCs). A positive correlation was found between disease severity and frequencies of circulating BDCA3(+) dendritic cells. These human equivalents of the rodent CD8(+) T cells migrate to tissues with a heavy parasite load and cause damage primarily through cytolysis. Implications: Malaria parasites may promote malaria pathogenesis by triggering MCs, which expand a unique class of dendritic cells with the subsequent activation of pathogenic CD8(+) T cells. However, MCs may have additional regulatory functions. Selective inhibition of MC activation may serve as an adjuvant treatment. |
|---|---|
| MeSH term(s) | Animals ; Antigens, Surface/analysis ; CD8-Positive T-Lymphocytes/immunology ; Child ; Dendritic Cells/chemistry ; Dendritic Cells/immunology ; Humans ; Malaria, Falciparum/immunology ; Mast Cells/immunology ; Membrane Proteins/blood ; Mice ; Plasmodium falciparum ; Severity of Illness Index |
| Chemical Substances | Antigens, Surface ; Membrane Proteins ; THBD protein, human ; flt3 ligand protein |
| Language | English |
| Publishing date | 2015-04-01 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 603113-4 |
| ISSN | 1879-114X ; 0149-2918 |
| ISSN (online) | 1879-114X |
| ISSN | 0149-2918 |
| DOI | 10.1016/j.clinthera.2015.03.014 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 1435: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 404: Show issues |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.